Vericel (NASDAQ:VCEL) 株価情報

VERICEL CORP

Vericel

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Vericel Corp

Canaccord Genuity analyst Joseph Vafi maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and maintains $17 price target.

News

Price Target

Analyst Ratings

Core Scientific, Inc. - Class A Common Stock

CORZ

Canaccord Genuity Maintains Buy on Core Scientific, Maintains $17 Price Target

Algonquin Power (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AQN#TSX">AQN</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.10 by 40 percent. This is unchanged from the same period last year. The company reported quarterly sales of $692.40 million which beat the analyst consensus estimate of $652.63 million by 6.09 percent. This is a 6.06 percent decrease over sales of $737.10 million the same period last year.

Earnings

Earnings Beats

TSX:AQN

Algonquin Power Q1 Adj. EPS $0.14 Beats $0.10 Estimate, Sales $692.40M Beat $652.63M Estimate

Melinda French Gates has endorsed the Gates Foundation&#8217;s decision to allocate its entire $200 billion endowment to global health by 2045.
What Happened: French Gates, in her interview with Fortune, <a href="https://fortune.com/2025/05/08/melinda-french-gates-interview-gates-foundation-impact-gavi/">applauded </a>the move, calling it &#8220;fantastic&#8221;. She emphasized that the foundation&#8217;s resources were always meant to be returned to society. 
French Gates highlighted&nbsp;that only 2% of philanthropy&nbsp;is directed towards organizations working on gender issues. She reiterated her commitment to bridging this gap by utilizing her resources. Last year, she pledged $1 billion&nbsp;to support organizations and individuals&nbsp;promoting gender equality and empowering women. This announcement comes at a time when U.S. investments in gender-focused initiatives in Africa are facing hurdles, partly due to President Trump's rhetoric against diversity, equity, and inclusion (DEI) efforts.
"I'm ready to set more of an agenda here in the United States," asserted French Gates.
Gates expressed disappointment with the cuts in USAID and stated that philanthropy by billionaires can never fill in the gap. &#8220;You can never fill the gap if the public sector pulls back. You just can't.&#8221;
She also stressed the importance of giving back, especially for the wealthiest. According to her, U.S. billionaires, who have benefited from the country&#8217;s infrastructure and health sector, have a moral obligation to give back to society.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track" target="_blank" rel="noreferrer noopener">Trump Fails To Impress America&#8217;s Young, Shows Poll As They Still Favor Biden — Only 15% Think US On Right Track &#8211; Benzinga</a>
Why It Matters: French Gates&#8217; commitment to global health and gender equality is not new. Earlier this month, she expressed concerns over the<a href="https://www.benzinga.com/markets/25/05/45186089/melinda-french-gates-takes-aim-at-elon-musks-doge-cuts-highlights-importance-of-philanthropy-and-government"> cuts made</a> by Elon Musk and the Department of Government Efficiency (DOGE) during President Donald Trump&#8217;s tenure. She emphasized the importance of government funding in expanding philanthropic efforts and warned about the potential devastating impacts of cuts to programs like USAID.
Her commitment to gender equality <a href="https://www.benzinga.com/tech/25/05/45162723/bill-gates-daughter-phoebe-says-mom-melinda-gave-tough-love-advice-after-investors-questioned-motherhood-plans-get-up-or-get-out-the-game">was also</a> evident when she gave practical advice to her daughter, Phoebe Gates, who faced questions from potential investors about future motherhood.
Moreover, her ex-spouse,&nbsp;Bill Gates, co-founder of&nbsp;Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), has also <a href="https://www.benzinga.com/markets/25/05/45286464/bill-gates-commits-99-of-his-remaining-fortune-to-gates-foundation-set-to-wind-down-in-20-years-somebody-should-give-more-money-than-i-did">pledged to donate</a> 99% of his remaining fortune to the Gates Foundation. This move further solidifies the Gates Foundation&#8217;s commitment to global health and philanthropy.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/global/25/05/45308582/pope-leo-xiv-didnt-spare-trump-administration-criticism-on-social-media-now-the-president-says-hes-excited-and-looking-forward-to-meeting-the-first-americ" target="_blank" rel="noreferrer noopener">Pope Leo XIV Didn&#8217;t Spare Trump Administration Criticism On Social Media — Now The President Says He&#8217;s &#8216;Excited&#8217; And Looking Forward To Meeting The First American Catholic Pontiff &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors

Equities

Markets

General

MSFT

Melinda French Gates Calls $200 Billion Gates Foundation Endowment For Global Health 'Fantastic,' Pledges Personal Funds For Gender Equality: '...Ready To Set More Of An Agenda Here In The United States'

Needham analyst Quinn Bolton reiterates Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and maintains $66 price target.

Reiteration

MCHP

Needham Reiterates Buy on Microchip Technology, Maintains $66 Price Target

Docebo (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#TSX">DCBO</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.22 by 22.73 percent. This is a 17.39 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $57.30 million which beat the analyst consensus estimate of $57.10 million by 0.34 percent. This is a 11.46 percent increase over sales of $51.40 million the same period last year.

TSX:DCBO

Docebo Q1 Adj. EPS $0.27 Beats $0.22 Estimate, Sales $57.30M Beat $57.10M Estimate

Canaccord Genuity analyst Joseph Vafi maintains Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) with a Buy and raises the price target from $130 to $179.

DAVE

Canaccord Genuity Maintains Buy on Dave, Raises Price Target to $179

Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) sees Q2 sales of $59.000 million-$59.200 million vs $59.05 million analyst estimate.

Guidance

DCBO

Docebo Sees Q2 Sales $59.000M-$59.200M vs $59.05M Est

HC Wainwright &amp; Co. analyst Scott Buck maintains Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) with a Buy and lowers the price target from $7 to $5.

DPRO

HC Wainwright & Co. Maintains Buy on Draganfly, Lowers Price Target to $5

GRAVITY Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRVY#NASDAQ">GRVY</a>) reported quarterly earnings of $2.15 per share. This is a 25.09 percent decrease over earnings of $2.87 per share from the same period last year. The company reported $93.23 million in sales this quarter. This is a 4.85 percent increase over sales of $88.92 million the same period last year.

GRVY

GRAVITY Co Q1 EPS $2.15, Sales $93.23M Up From $88.92M YoY

Cineplex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CGX#TSX">CGX</a>) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.34) by 70.59 percent. This is a 41.41 percent increase over losses of $(0.99) per share from the same period last year. The company reported quarterly sales of $264.28 million which missed the analyst consensus estimate of $270.99 million by 2.47 percent. This is a 10.34 percent decrease over sales of $294.76 million the same period last year.

Earnings Misses

TSX:CGX

Cineplex Q1 EPS $(0.58) Misses $(0.34) Estimate, Sales $264.28M Miss $270.99M Estimate

Needham analyst Quinn Bolton maintains D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) with a Buy and raises the price target from $8.5 to $13.

QBTS

Needham Maintains Buy on D-Wave Quantum, Raises Price Target to $13

Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.10) by 100 percent. This is a 100 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $286.36 million which beat the analyst consensus estimate of $279.75 million by 2.36 percent. This is a 31.98 percent increase over sales of $216.96 million the same period last year.

Outbrain Q1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $286.36M Beat $279.75M Estimate

Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.21 by 28.57 percent. This is a 17.39 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $57.30 million which beat the analyst consensus estimate of $57.09 million by 0.35 percent. This is a 11.46 percent increase over sales of $51.40 million the same period last year.

Docebo Q1 Adj. EPS $0.27 Beats $0.21 Estimate, Sales $57.30M Beat $57.09M Estimate

TXNM

TXNM Energy Affirms FY2025 Adj EPS Guidance of $2.74-$2.84 vs $2.79 Est, And Maintained Its Long-term Earnings Growth Target Of 7% To 9%

Essent Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESNT#NYSE">ESNT</a>) reported quarterly earnings of $1.69 per share which beat the analyst consensus estimate of $1.68 by 0.6 percent. This is a 0.59 percent decrease over earnings of $1.70 per share from the same period last year. The company reported quarterly sales of $317.56 million which beat the analyst consensus estimate of $310.29 million by 2.34 percent. This is a 6.44 percent increase over sales of $298.36 million the same period last year.

ESNT

Essent Group Q1 EPS $1.69 Beats $1.68 Estimate, Sales $317.56M Beat $310.29M Estimate

Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) affirms FY2025 Adj EPS guidance from $2.70-$2.90 to $2.70-$2.90 vs $2.80 analyst estimate. Lowers FY2025 sales outlook from $1.07 billion-$1.09 billion to $1.07 billion-$1.09 billion vs $1.09 billion estimate.

EMBC

Embecta Affirms FY2025 Adj EPS Guidance of $2.70-$2.90 vs $2.80 Est; Lowers FY2025 Sales Guidance of $1.07B-$1.09B vs $1.09B Est

EchoStar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.69) by 2.9 percent. This is a 77.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $3.87 billion which met the analyst consensus estimate. This is a 3.61 percent decrease over sales of $4.01 billion the same period last year.

SATS

EchoStar Q1 EPS $(0.71) Misses $(0.69) Estimate, Sales $3.87B Inline

GPUS

Hyperscale Data Announced That Its Indirectly Owned Subsidiary BitNile.Com Officially Launched The Nile Coin On The Solana Blockchain On May 3

TXNM Energy Q1 2025 Adj. EPS $0.19 Misses $0.20 Estimate, Sales $482.79M Beat $432.72M Estimate

Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.53 by 32.08 percent. This is a 4.48 percent increase over earnings of $0.67 per share from the same period last year. The company reported quarterly sales of $259.00 million which beat the analyst consensus estimate of $253.94 million by 1.99 percent. This is a 9.82 percent decrease over sales of $287.20 million the same period last year.

Comments

Vericel

ニュース

パートナーシップ

ベンジンガ・グローバル